MX358636B - Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. - Google Patents

Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.

Info

Publication number
MX358636B
MX358636B MX2012008300A MX2012008300A MX358636B MX 358636 B MX358636 B MX 358636B MX 2012008300 A MX2012008300 A MX 2012008300A MX 2012008300 A MX2012008300 A MX 2012008300A MX 358636 B MX358636 B MX 358636B
Authority
MX
Mexico
Prior art keywords
nsaid
encapsulation
concentration
formulation
blando
Prior art date
Application number
MX2012008300A
Other languages
English (en)
Spanish (es)
Other versions
MX2012008300A (es
Inventor
Lopez John
Draper Peter
Vashishtha Sankalp
Klassen Nancy
Armstrong Christina
Original Assignee
Accucaps Industries Ltd Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accucaps Industries Ltd Star filed Critical Accucaps Industries Ltd Star
Publication of MX2012008300A publication Critical patent/MX2012008300A/es
Publication of MX358636B publication Critical patent/MX358636B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012008300A 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. MX358636B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Publications (2)

Publication Number Publication Date
MX2012008300A MX2012008300A (es) 2012-11-23
MX358636B true MX358636B (es) 2018-08-29

Family

ID=44303618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008300A MX358636B (es) 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.

Country Status (13)

Country Link
US (4) US9480667B2 (https=)
EP (2) EP2525789B1 (https=)
JP (2) JP5975884B2 (https=)
AU (1) AU2011207061B2 (https=)
CA (1) CA2690488C (https=)
DK (1) DK2525789T3 (https=)
ES (1) ES2880813T3 (https=)
HU (1) HUE055771T2 (https=)
MX (1) MX358636B (https=)
PL (1) PL2525789T3 (https=)
PT (1) PT2525789T (https=)
SI (1) SI2525789T1 (https=)
WO (1) WO2011088553A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业(武汉)有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
BR112021021414A2 (pt) * 2019-04-26 2022-02-15 Scherer Technologies Llc R P Composição do mini softgel de naproxeno
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
MX9602955A (es) * 1994-01-24 1997-06-28 Procter & Gamble Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
EP1605916A4 (en) * 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLVENT SYSTEM OF A SMOOTH MEDICAMENT WITH IMPROVED ELUTION RATE
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US7582679B2 (en) * 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Also Published As

Publication number Publication date
US20200046662A1 (en) 2020-02-13
JP2013517304A (ja) 2013-05-16
US20130011470A1 (en) 2013-01-10
EP2525789B1 (en) 2021-06-02
EP2525789A1 (en) 2012-11-28
US12605348B2 (en) 2026-04-21
PT2525789T (pt) 2021-07-19
MX2012008300A (es) 2012-11-23
US20170020832A1 (en) 2017-01-26
WO2011088553A1 (en) 2011-07-28
CA2690488A1 (en) 2011-07-19
ES2880813T3 (es) 2021-11-25
EP2525789A4 (en) 2014-04-30
CA2690488C (en) 2013-06-11
EP3909567B1 (en) 2026-04-29
HUE055771T2 (hu) 2021-12-28
US10463637B2 (en) 2019-11-05
PL2525789T3 (pl) 2022-01-03
SI2525789T1 (sl) 2021-12-31
US9480667B2 (en) 2016-11-01
AU2011207061A1 (en) 2012-07-26
US11896566B2 (en) 2024-02-13
DK2525789T3 (da) 2021-07-19
JP2016094462A (ja) 2016-05-26
EP3909567A1 (en) 2021-11-17
AU2011207061B2 (en) 2015-05-28
US20240139132A1 (en) 2024-05-02
JP5975884B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
MX358636B (es) Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CR10728A (es) Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2012003204A (es) Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CR20150402A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
CY1123895T1 (el) Φαρμακευτικα σκευασματα λοραταδινης για εγκλεισμο σε καψακια και συνδυασμοι αυτων
HRP20181607T1 (hr) Stabilne oralne otopine za kombinirane aktivne farmaceutske sastojke
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
MX2016014256A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
DOP2016000008A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
PL395069A1 (pl) Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
EA201491995A1 (ru) Пероральная лекарственная форма
EA201590732A1 (ru) Диспергируемая таблетка
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
ES2468665B1 (es) Composición farmacéutica de sulfato de condroitina y celecoxib

Legal Events

Date Code Title Description
FG Grant or registration